Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895956 · ClinicalTrials.gov registry record · Phase 4
Intra-sheath vs Extra-sheath Injection for De Quervain's Tenosynovitis
A Phase 4 study of De Quervain Tenosynovitis, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04895956: Recruiting Phase 4 study of De Quervain Tenosynovitis, sponsored by University of California, Davis.
NCT04895956 is a Phase 4 study of De Quervain Tenosynovitis that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 80 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04895956, a Phase 4 study of De Quervain Tenosynovitis, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the study is to determine whether or not extra-sheath steroid injections are inferior to intra-sheath steroid injections in the treatment of DeQuervain's Tenosynovitis. Patients will be randomized to either the intra-sheath group or the extra-sheath group and their pre-injection level of pain will be assessed using the visual analog scale. Appropriate injections will then be administered by 1 of 3 UC Davis hand surgeons. Six weeks post injection the patients will be reassessed using the visual analog scale and their score at 6 weeks will be compared to their pre-injection score.
Primary Outcome
The difference between pre-injection and 6 weeks post-injection visual analog scale scores in both the experimental extra-sheath injection and control intra-sheath injection. The visual analog pain scale is a widely used test to effectively measure pain(9). The visual analog scale we will be using is a 100mm horizontal line with no numbers and only written descriptors on either end of the line. The written descriptor on the left side of the line will be "no pain" and the descriptor on the right
Conditions Studied
Interventions
- DEVICE Ultrasound
- PROCEDURE Intra-sheath injection
- PROCEDURE Extra-sheath injection
Study Locations (1)
California
- UC Davis Health, Department of Orthopaedics - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 4 |
What NCT04895956 shows while recruiting
NCT04895956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with De Quervain Tenosynovitis appearing as the primary indexed condition, and to 3 interventions - of which Ultrasound is the first listed.
NCT04895956 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04895956 about?
NCT04895956 is a clinical study titled "Intra-sheath vs Extra-sheath Injection for De Quervain's Tenosynovitis". The aim of the study is to determine whether or not extra-sheath steroid injections are inferior to intra-sheath steroid injections in the treatment of DeQuervain's Tenosynovitis. Patients will be randomized to either the intra-sheath group or the extra-sheath group and their pre-injection level of...
What is the current status of trial NCT04895956?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2022-01-24. Estimated completion is 2026-06-01.
What conditions does trial NCT04895956 study?
This clinical trial studies the following conditions: De Quervain Tenosynovitis.
What interventions are being tested in trial NCT04895956?
The interventions under investigation include: Ultrasound (DEVICE), Intra-sheath injection (PROCEDURE), Extra-sheath injection (PROCEDURE).
Who is sponsoring clinical trial NCT04895956?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04895956 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04895956's enrollment target sits among peer trials
80 946th of 2000 higher than 1,022 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI